UK Biotech Monument Uses Repurposed Drugs To Target CNS Conditions
Initial Programs In Cognitive Impairment In Schizophrenia, Post-Operative Cognitive Decline
Executive Summary
Emerging Company Profile: Monument Therapeutics’ novel approach to CNS drug development focuses on repurposing existing drugs with the aid of digital biomarkers.
You may also be interested in...
Provepharm’s CEO Plans Fresh Acquisitions After Raising €120m
France’s Provepharm Life Solutions, which finds new uses for known mature molecules, in particular antidotes and surgical dyes, by improving their efficacy and maximizing their therapeutic potential, has fresh funds to expand its portfolio.
Provention Maps Possible Regulatory Path For Troubled Teplizumab
Provention has been working hard collecting necessary data for a potential BLA resubmission for teplizumab in patients at risk of developing type 1 diabetes after receiving a complete response letter in July. Hopes rest on a Type A meeting with the FDA in Q4.
Sanofi’s Kadmon Bolt-On Bolsters Its General Medicine Division
Sanofi’s $1.9bn cash purchase of Kadmon surprised many analysts, coming as a bolt-on for the French pharma’s general medicines transplant portfolio rather than its specialty care pipeline, but the overall view was that it made sense.